US2023263869A1PendingUtilityA1
Suture line administration technique using botulinum toxins
Est. expiryApr 3, 2028(~1.7 yrs left)· nominal 20-yr term from priority
Inventors:Andrew M. Blumenfeld
A61K 38/4893C12Y 304/24069A61P 25/00A61P 25/06
84
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
Claims
exact text as granted — not AI-modified1 . A method for treating a patient suffering from a headache, comprising the step of administering a Clostridial toxin in the vicinity of at least one suture line of the patient's skull, wherein the administration alleviates at least one symptom of the headache, thereby treating the patient suffering from the headache.
2 . The method according to claim 1 , wherein the Clostridial neurotoxin is a botulinum toxin.
3 . The method according to claim 1 , wherein the headache is selected from the group consisting of a sinus headache, a tension headache, a migraine headache, a cluster headache and a cervicogenic headache.
4 . The method according to claim 1 , wherein the at least one suture line is selected from the group consisting of frontal suture, squamous suture, occipitomastoid suture, coronal suture, lambdoid suture and sagittal suture.
5 . The method according to claim 2 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.
6 . The method according to claim 5 , wherein the botulinum toxin is a botulinum toxin type A.
7 . The method according to claim 6 , wherein the botulinum toxin type A is administered in an amount from about 5 units to about 1000 units.
8 . The method according to claim 1 , wherein the headache is an episodic migraine or a chronic migraine.
9 . The method of claim 1 , further comprising the step of administering the Clostridial toxin in the vicinity of a second suture line.
10 . The method of claim 1 , wherein the Clostridial neurotoxin is administered at about 1.5 cm, about 1.0 cm, or about 0.5 cm from the at least one suture line.
11 . A method for alleviating a headache pain, comprising the step of determining the location of at least one suture line; and administering a therapeutically effective amount of a botulinum toxin type A to a patient in need thereof, wherein the botulinum toxin type A is administered in the vicinity of the at least one suture line of the patient's skull, thereby alleviating the headache pain.
12 . The method of claim 11 , wherein the botulinum toxin type A is onabotulinumtoxinA.
13 . The method of claim 12 , wherein the therapeutically effective amount of the administered botulinum toxin type A is from about 60 units to about 100 units.
14 . The method according to claim 11 , wherein the at least one suture is selected from the group consisting of frontal suture, squamous suture, coronal suture, lambdoid suture, occipitomastoid suture and sagittal suture.
15 . The method of claim 11 , wherein the administration step includes the step of inserting a needle of a syringe containing the botulinum toxin type A at a needle penetration point and positioning the needle along the at least one suture line so that the botulinum toxin type A is administered linearly along at least a portion of the at least one suture line.Join the waitlist — get patent alerts
Track US2023263869A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.